Journal of Shandong University (Health Sciences) ›› 2021, Vol. 59 ›› Issue (9): 57-63.doi: 10.6040/j.issn.1671-7554.0.2021.0953

Previous Articles     Next Articles

Establishing the novel pharmacogenomics of head and neck cancer based on preclinical tumor models: necessity and prospect

SUN Shuyang, ZHANG Zhiyuan   

  1. Department of Oromaxillofacial Head and Neck Oncology, Shanghai Ninth Peoples Hospital, Shanghai Jiao Tong University School of Medicine;
    College of Stomatology, Shanghai Jiao Tong University;
    National Center for Stomatology;
    National Clinical Research Center for Oral Diseases;
    Shanghai Key Laboratory of Stomatology, Shanghai 200011, China
  • Published:2021-10-15

Abstract: Head and neck cancer is the seventh common malignant tumor in the world. For more than 60% patients, the diagnosis is made at an intermediate or advanced stage. Although the development of targeted therapy and immunotherapy has significantly promoted the transformation of therapeutic strategies of head and neck cancer, there is still an urgent need to expand the clinical benefits. Preclinical models of cancer, which maintain the genetic and phenotypic heterogeneity from their parental tumors, have been widely used in the preclinical drug screening and validation. By matching genomics and drug response, pharmacogenomics can stratify patients based on tumor heterogeneity, optimize treatment strategies, and discover new therapeutic targets. This paper outlines the history of pharmacogenomics, and discusses the necessity and feasibility of developing pharmacogenomics with the aid of preclinical models in the context of the current treatment status and tumor heterogeneity of head and neck cancer.

Key words: Pharmacogenomics, Patient-derived xenografts, Patient-derived cancer cells, Tumor heterogeneity, Head and neck cancer

CLC Number: 

  • R739.8
[1] Turajlic S, Sottoriva A, Graham T, et al. Resolving genetic heterogeneity in cancer [J]. Nat Rev Genet, 2019, 20(7): 404-416.
[2] Siegel RL, Miller KD, Fuchs HE, et al. Cancer statistics, 2021 [J]. Ca Cancer J Clin, 2021, 71(1): 7-33.
[3] Chow LQM. Head and neck cancer [J]. N Engl J Med, 2020, 382(1): 60-72.
[4] Roden DM, McLeod HL, Relling MV, et al. Pharmacogenomics [J]. Lancet, 2019, 394(10197): 521-532.
[5] Motulsky AG. Drug reactions enzymes, and biochemical genetics [J]. JAMA, 1957, 165(7): 835-837.
[6] Lehmann H, Ryan E. The familial incidence of low pseudocholinesterase level [J]. Lancet, 1956, 271(6934): 124.
[7] Kalow W, Staron N. On distribution and inheritance of atypical forms of human serum cholinesterase, as indicated by dibucaine numbers [J]. Can J Biochem Physiol, 1957, 35(12): 1305-1320.
[8] Alving AS, Carson PE, Flanagan CL, et al. Enzymatic deficiency in primaquine-sensitive erythrocytes [J]. Science, 1956, 124(3220): 484-485.
[9] Relling MV, Evans WE. Pharmacogenomics in the clinic [J]. Nature, 2015, 526(7573): 343-350.
[10] 黄民. 药物基因组学与合理用药 [J]. 药学进展, 2018, 42(4): 241-242. HUANG Min. Pharmacogenomics and rational drug use [J]. Progress in Pharmaceutical Sciences, 2018, 42(4): 241-242.
[11] Earl HM, Hiller L, Vallier A-L, et al. 6 versus 12 months of adjuvant trastuzumab for HER2-positive early breast cancer(PERSEPHONE): 4-year disease-free survival results of a randomised phase 3 non-inferiority trial [J]. Lancet, 2019, 393(10191): 2599-2612.
[12] Hehlmann R, Lauseker M, SauBele S, et al. Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV and impact of non-CML determinants [J]. Leukemia, 2017, 31(11): 2398-2406.
[13] Maemondo M, Inoue A, Kobayashi K, et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR [J]. N Engl J Med, 2010, 362(25): 2380-2388.
[14] Vasan N, Baselga J, Hyman DM. A view on drug resistance in cancer [J]. Nature, 2019, 575(7782): 299-309.
[15] Kim C, Gao R, Sei E, et al. Chemoresistance evolution in triple-negative breast cancer delineated by single-cell sequencing [J]. Cell, 2018, 173(4): 879-893.
[16] Marusyk A, Janiszewska M, Polyak K. Intratumor heterogeneity: the rosetta stone of therapy resistance [J]. Cancer Cell, 2020, 37(4): 471-484.
[17] Hong SP, Chan TE, Lombardo Y, et al. Single-cell transcriptomics reveals multi-step adaptations to endocrine therapy [J]. Nat Commun, 2019, 10(1): 3840.
[18] Shaffer SM, Dunagin MC, Torborg SR, et al. Rare cell variability and drug-induced reprogramming as a mode of cancer drug resistance [J]. Nature, 2017, 546(7658): 431-435.
[19] Murtuza A, Bulbul A, Shen JP, et al. Novel third-generation EGFR tyrosine kinase inhibitors and strategies to overcome therapeutic resistance in lung cancer [J]. Cancer Res, 2019, 79(4): 689-698.
[20] Mok TS, Wu YL, Ahn MJ, et al. Osimertinib or platinum-pemetrexed in EGFR T790M-positive lung cancer [J]. N Engl J Med, 2017, 376(7): 629-640.
[21] Piotrowska Z, Isozaki H, Lennerz JK, et al. Landscape of acquired resistance to osimertinib in EGFR-mutant NSCLC and clinical validation of combined EGFR and RET inhibition with osimertinib and BLU-667 for acquired RET fusion [J]. Cancer Discov, 2018, 8(12): 1529-1539.
[22] Tanaka K, Yu HA, Yang S, et al. Targeting aurora B kinase prevents and overcomes resistance to EGFR inhibitors in lung cancer by enhancing BIM- and PUMA-mediated apoptosis [J]. Cancer Cell, 2021, S1535-6108(21)00383-4.
[23] D'Cruz AK, Vaish R, Kapre N, et al. Elective versus therapeutic neck dissection in node-negative oral cancer [J]. N Engl J Med, 2015, 373(6): 521-529.
[24] Santuray RT, Johnson DE, Grandis JR. New therapies in head and neck cancer [J]. Trends Cancer, 2018, 4(5): 385-396.
[25] Vermorken JB, Trigo J, Hitt R, et al. Open-label, uncontrolled, multicenter phase II study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck who failed to respond to platinum-based therapy [J]. J Clin Oncol, 2007, 25(16): 2171-2177.
[26] Kim HS, Kwon HJ, Jung I, et al. Phase II clinical and exploratory biomarker study of dacomitinib in patients with recurrent and/or metastatic squamous cell carcinoma of head and neck [J]. Clin Cancer Res, 2015, 21(3): 544-552.
[27] William WN, Papadimitrakopoulou V, Lee JJ, et al. Erlotinib and the Risk of Oral Cancer: The Erlotinib Prevention of Oral Cancer(EPOC)Randomized Clinical Trial [J]. JAMA Oncol, 2016, 2(2): 209-216.
[28] Hedberg ML, Peyser ND, Bauman JE, et al. Use of nonsteroidal anti-inflammatory drugs predicts improved patient survival for -altered head and neck cancer [J]. J Exp Med, 2019, 216(2): 419-427.
[29] Adkins D, Ley J, Neupane P, et al. Palbociclib and cetuximab in platinum-resistant and in cetuximab-resistant human papillomavirus-unrelated head and neck cancer: a multicentre, multigroup, phase 2 trial [J]. Lancet Oncol, 2019, 20(9): 1295-1305.
[30] Burtness B, Harrington KJ, Greil R, et al. Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck(KEYNOTE-048): a randomised, open-label, phase 3 study [J]. Lancet, 2019, 394(10212): 1915-1928.
[31] Sacco AG, Chen R, Worden FP, et al. Pembrolizumab plus cetuximab in patients with recurrent or metastatic head and neck squamous cell carcinoma: an open-label, multi-arm, non-randomised, multicentre, phase 2 trial [J]. Lancet Oncol, 2021, 22(6): 883-892.
[32] Seiwert TY, Burtness B, Mehra R, et al. Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck(KEYNOTE-012): an open-label, multicentre, phase 1b trial [J]. Lancet Oncol, 2016, 17(7): 956-965.
[33] Cancer Genome Atlas Network. Comprehensive genomic characterization of head and neck squamous cell carcinomas [J]. Nature, 2015, 517(7536): 576-582.
[34] McGranahan N, Swanton C. Clonal heterogeneity and tumor evolution: past, present, and the future [J]. Cell, 2017, 168(4): 613-628.
[35] Elkabets M, Pazarentzos E, Juric D, et al. AXL mediates resistance to PI3Kα inhibition by activating the EGFR/PKC/mTOR axis in head and neck and esophageal squamous cell carcinomas [J]. Cancer Cell, 2015, 27(4): 533-546.
[36] Shu S, Wu HJ, Ge JY, et al. Synthetic lethal and resistance interactions with BET bromodomain inhibitors in triple-negative breast cancer [J]. Mol Cell, 2020, 78(6): 1096-1113.
[37] Amodio V, Yaeger R, Arcella P, et al. EGFR blockade reverts resistance to KRAS G12C inhibition in colorectal cancer [J]. Cancer Discov, 2020, 10(8): 1129-1139.
[38] Zhou R, Shi C, Tao W, et al. Analysis of mucosal melanoma whole-genome landscapes reveals clinically relevant genomic aberrations [J]. Clin Cancer Res, 2019, 25(12): 3548-3560.
[39] Gao H, Korn JM, Ferretti S, et al. High-throughput screening using patient-derived tumor xenografts to predict clinical trial drug response [J]. Nat Med, 2015, 21(11): 1318-1325.
[40] Gengenbacher N, Singhal M, Augustin HG. Preclinical mouse solid tumour models: status quo, challenges and perspectives [J]. Nat Rev Cancer, 2017, 17(12): 751-765.
[41] Izumchenko E, Paz K, Ciznadija D, et al. Patient-derived xenografts effectively capture responses to oncology therapy in a heterogeneous cohort of patients with solid tumors [J]. Ann Oncol, 2017, 28(10): 2595-2605.
[42] Barretina J, Caponigro G, Stransky N, et al. The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity [J]. Nature, 2012, 483(7391): 603-607.
[43] Haibe-Kains B, El-Hachem N, Birkbak NJ, et al. Inconsistency in large pharmacogenomic studies [J]. Nature, 2013, 504(7480): 389-393.
[44] Cancer Cell Line Encyclopedia Consortium, Genomics of Drug Sensitivity in Cancer Consortium. Pharmacogenomic agreement between two cancer cell line data sets [J]. Nature, 2015, 528(7580): 84-87.
[45] Haverty PM, Lin E, Tan J, et al. Reproducible pharmacogenomic profiling of cancer cell line panels [J]. Nature, 2016, 533(7603): 333-337.
[46] Bruna A, Rueda OM, Greenwood W, et al. A biobank of breast cancer explants with preserved intra-tumor heterogeneity to screen anticancer compounds [J]. Cell, 2016, 167(1): 260-274..
[47] Qiu Z, Li H, Zhang Z, et al. A pharmacogenomic landscape in human liver cancers [J]. Cancer Cell, 2019, 36(2):179-193.
[48] Sa JK, Hwang JR, Cho Y-J, et al. Pharmacogenomic analysis of patient-derived tumor cells in gynecologic cancers [J]. Genome Biol, 2019, 20(1): 253.
[49] Sa JK, Hong JY, Lee I-K, et al. Comprehensive pharmacogenomic characterization of gastric cancer [J]. Genome Med, 2020, 12(1): 17.
[50] Byrne AT, Alferez DG, Amant F, et al. Interrogating open issues in cancer precision medicine with patient-derived xenografts [J]. Nat Rev Cancer, 2017, 17(4): 254-268.
[1] WANG Ying, ZHANG Yafei, WEN Yong. YAP gene overexpression promotes tongue squamous carcinoma growth through PI3K/AKT/mTOR signaling pathway [J]. Journal of Shandong University (Health Sciences), 2020, 58(2): 21-28.
[2] CHEN Xiyan, WANG Qi, GU Weiting, WEN Yong. Effects of TAZ knockdown on the proliferation and apoptosis of TSCC cell line CAL27 and the molecular mechanism [J]. Journal of Shandong University (Health Sciences), 2018, 56(10): 79-85.
[3] MA Xue, ZHANG Bin, HAN Chunyao, LIU Mingyuan, HAO Lijing, GE Shuqing, XUE Zhongyuan. Down-regulation of α-catulin inhibits the invasion and migration of human tongue squamous cancer cell line Tscca in vitro [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2016, 54(6): 12-15.
[4] HAO Lijing, GE Shuqing, WANG Shufen, ZHENG Wenjiao, ZHANG Bin. Effects of sorafenib on the proliferation and apoptosis of cisplatin-resistant tongue cancer cells in vitro [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2016, 54(1): 17-21.
[5] WANG Hua-chun1, HUANG Sheng-yun2, XIE Hong-jun1, LIU Wen-lei1, ZHANG Jie3, ZHANG Dong-sheng1,2. Expression and clinical significance of protein tyrosine phosphatase SHP-2 in oral squamous cell carcinoma [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2014, 52(2): 82-85.
[6] LIU Shuo-shuo, ZHANG Bin, GUO Ting-ting, DONG Xiao-ting. Effect of PTEN transfection on human tongue squamous carcinoma cell line SCC-4 and its mechanism [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2013, 51(1): 42-45.
[7] ZHANG Dong1, HE Hai-xian2, DONG Li-xin3, CHEN Zhenggang4, WANG Yu-min1, LIU Shao-hua1. Expression of Galectin-1 in squamous cell carcinoma of the tongue and correlation with clinicopathological parameters [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2011, 49(11): 138-.
[8] ZHANG Yan-sheng,LIU Shao-hua,WEI Feng-cai,SUN Shan-zhen. Expressions of HGF and its receptor in oral squamous cell carcinoma and neck lymph nodes [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2008, 46(4): 420-423.
[9] WANG Zhen-guang,SUN Shan-zhen,SHI Lin,WANG Dong-guan. Gene expression regulation between tongue squamous cell carcinoma cell line Tca-8113 and normal tongue mucosa fibroblasts [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2007, 45(5): 446-449.
[10] HUANG Sheng-yun,ZHANG Dong-sheng,ZHANG Shi-zhou,LIU Gui-jun,ZHAO Yue-ran,WANG Lai-cheng,LIU Yi-qing. Construction of recombination expression vector pIRES-CD and pIRES-TK and their expression in ACC-2 cells [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2007, 45(2): 117-123.
[11] . Expression and methylation of p16 in carcinoma ex pleomorphic adenoma of the parotid gland [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2009, 47(11): 108-110.
[12] LIU Guanyi, YANG Liyuan, FU Zhentao, XU Aiqiang, GUO Xiaolei. Incidence and mortality of oral cancer in Shandong Province in 2014 [J]. Journal of Shandong University (Health Sciences), 2019, 57(7): 102-107.
Viewed
Full text


Abstract

Cited

  Shared   
  Discussed   
[1] ZHANG Jie,LI Zhen-hua,SUN Jin-hao,BAO Li-hua,LIU Yue-peng. Protective effects of the invariable magnetic field on oxidative injured Schwann cells[J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2007, 45(3): 229 -232 .
[2] . [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2007, 45(10): 995 .
[3] JIANG Hong-ju,LI Run-zhi, WANG Ying,XU Dong-mei,ZHANG Mei,ZHANG Yun,LI Ji-fu. Relationship between the plasma level of matrix metalloproteinase-9 and structural characteristics of plaques and percutaneous coronary intervention [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2008, 46(10): 966 -970 .
[4] ZHENG Min,HAO Yue-wei,LIU Xue-ping,ZHAO Ting-ting. Relationship between the HPA-2 and Kozak sequence polymorphism of platelet membrane glycoprotein and cerebral infarction[J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2008, 46(3): 292 -295 .
[5] . [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2008, 46(8): 828 -830 .
[6] . [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2009, 47(9): 5 -6 .
[7] NIU Rui,LIU Bo,SHAO Ming-ju,WANG Wei. mRNA expression of lunx in regional lymph nodes of non-small cell lung cancer and its correlation with prognosis[J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2007, 45(9): 884 -885 .
[8] JIAO Fang-fang,LIU Shi-qing,LI Fei,LI Chang-sheng,WANG Qin,SUN Qing,LU Wei. Therapeutic effects of Huayulifei on expression of SMAD7 and TGF-β in rats with bleomycin-induced pulmonary fibrosis[J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2007, 45(10): 1054 -1058 .
[9] ZHAO Ying, YAN Lei, ZHANG Hui, YU Peng, LI Ming-jiang, ZHAO Xing-bo. Expression of SPAG9 in patients with serous epithelial ovarian tumors[J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2012, 50(2): 98 .
[10] WANG Shu-qin,QI Feng,WU Jian-bo,SUN Bao-zhu. Effect of calcium in ropivacaine-induced smooth muscle contraction of the aorta in rats in vitro[J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2008, 46(8): 773 -776 .